David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) General Counsel David I. Sandoval sold 4,466 shares of MaxCyte stock in a transaction on Monday, January 13th. The stock was sold at an average price of $4.54, for a total transaction of $20,275.64. Following the completion of the sale, the general counsel now owns 41,447 shares of the company’s stock, valued at approximately $188,169.38. This trade represents a 9.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

MaxCyte Price Performance

NASDAQ:MXCT traded down $0.27 during mid-day trading on Tuesday, reaching $4.64. The stock had a trading volume of 1,018,515 shares, compared to its average volume of 661,274. The company has a market capitalization of $490.50 million, a price-to-earnings ratio of -13.65 and a beta of 1.29. The stock’s 50 day simple moving average is $3.92 and its two-hundred day simple moving average is $4.02. MaxCyte, Inc. has a 1-year low of $3.16 and a 1-year high of $5.32.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The firm had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. Sell-side analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MXCT. Verition Fund Management LLC raised its stake in MaxCyte by 39.5% during the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock valued at $83,000 after acquiring an additional 6,045 shares in the last quarter. Creative Planning lifted its holdings in shares of MaxCyte by 33.6% in the third quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after buying an additional 7,212 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of MaxCyte by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after purchasing an additional 7,930 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in MaxCyte by 25.0% in the second quarter. The Manufacturers Life Insurance Company now owns 42,289 shares of the company’s stock worth $166,000 after buying an additional 8,454 shares during the last quarter. Finally, Chevy Chase Trust Holdings LLC lifted its position in shares of MaxCyte by 0.7% during the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 1,332,048 shares of the company’s stock valued at $5,182,000 after acquiring an additional 9,488 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.